PTC THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
SCHMERTZLER MICHAEL sold 20,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $67.49 ($66.58–$68.45, $1.35M total) across 4 trades over 2026-09-16 to 2026-09-17 under a Rule 10b5-1 trading plan.
Leerink Partners rated PTC Therapeutics (PTCT) 'Outperform' with a $98 target. GuruFocus values PTCT at $38.71, indicating 71.7% overvaluation. Insiders sold $19.5M in shares. PTCT has a GF Score of 57, showing moderate performance with strengths in momentum but weaknesses in financials.
PTC Therapeutics (PTCT) director Michael Schmertzler sold 20,000 shares worth $1.35m via a 10b5-1 plan, averaging $67.34-$68.67 per share. He still owns 1.32m shares. PTCT stock is down 5% in a week and 13% YTD, deemed overvalued by InvestingPro. The company recently beat Q2 earnings estimates, reporting $0.92 EPS on $361m revenue, and raised full-year guidance. PTCT ended Q2 with $2.23bn in cash.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PTCT (PTC THERAPEUTICS, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent PTCT coverage spans insider activity, financial news and technology.
In the last 30 days, PTCT insiders filed 14 SEC Form 4 transactions — no purchases and 14 sales ($5.4M). The most active reporter was SCHMERTZLER MICHAEL with 14 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal reduced confidence, but size is modest relative to float.
Analyst upgrade may support short‑term price upside but overvaluation concerns remain.
Insider sale may signal lack of confidence, potentially pressuring the stock short term.
The insider sale may signal weak confidence and could pressure the stock short term.
The insider sale modestly increases supply pressure but size is small relative to float.
AlphAI scores every news story that mentions PTCT with an AI model for sentiment and relevance, and aggregates insider trades from PTC THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SCHMERTZLER MICHAEL sold 20,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $67.49 ($66.58–$68.45, $1.35M total) across 4 trades over 2026-09-16 to 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readLeerink Partners rated PTC Therapeutics (PTCT) 'Outperform' with a $98 target. GuruFocus values PTCT at $38.71, indicating 71.7% overvaluation. Insiders sold $19.5M in shares. PTCT has a GF Score of 57, showing moderate performance with strengths in momentum but weaknesses in financials.
1 min readPTC Therapeutics (PTCT) director Michael Schmertzler sold 20,000 shares worth $1.35m via a 10b5-1 plan, averaging $67.34-$68.67 per share. He still owns 1.32m shares. PTCT stock is down 5% in a week and 13% YTD, deemed overvalued by InvestingPro. The company recently beat Q2 earnings estimates, reporting $0.92 EPS on $361m revenue, and raised full-year guidance. PTCT ended Q2 with $2.23bn in cash.
1 min readSCHMERTZLER MICHAEL sold 20,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $67.59 ($67.34–$68.67, $1.35M total) across 3 trades over 2026-09-09 to 2026-09-10 under a Rule 10b5-1 trading plan.
1 min readPTC Therapeutics (PTCT) director Michael Schmertzler sold 25,000 shares of common stock on August 26–27, 2026, under a Rule 10b5-1 trading plan. The sales were executed in open-market transactions at weighted average prices ranging from $71.55 to $73.18 per share. Schmertzler directly holds 163,266 shares of common stock as of August 26, 2026.
1 min readSCHMERTZLER MICHAEL sold 25,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $72.26 ($71.55–$73.18, $1.81M total) across 4 trades over 2026-08-26 to 2026-08-27 under a Rule 10b5-1 trading plan.
1 min readPTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 25, 2026, PTC Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Sangamo Therapeutics, Inc. (“Sangamo”), pursuant to which the Company agreed to acquire
2 min readPTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti
3 min readPTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.
2 min readPTC Therapeutics (PTCT) presented data on Sephience at a metabolic disorders symposium. Clinical trials and real-world data showed significant reductions in blood phenylalanine levels and dietary liberalization in PKU patients. Sephience is approved in the U.S., EU, and Japan. The drug carries warnings about bleeding risk and hypophenylalaninemia. PKU affects about 58,000 people globally.
2 min read